Apple, Inc AAPL
S&P 500 ETF Trust SPDR SPY
Alphabet Inc. - Class A Shares GOOGL
Microsoft Corporation MSFT
Meta Platforms Inc META
Netflix, Inc. NFLX
Amazon.com Inc. AMZN
Spotify Technology SA SPOT

MBX Biosciences, Inc. Common Stock, Common Stock

MBX

NSQ

$20.36

+$0.09

(0.44%)

Industry: Biotechnology Sector: Health Care

Analyst Forecast

Overview Returns Financials Ratios News FAQs

Price Chart

Key Metrics

Market Cap info-icon

This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.

$676.25M

P/E Ratio

This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.

Volume

This is the total number of shares traded during the most recent trading day.

2.38M

Avg Volume info-icon

This is the average number of shares traded during the most recent 30 days.

Dividend Yield info-icon

This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).

0.00%

Beta

This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.

52-week Range
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).

$15.31 L

$27.5 H

$20.36

About MBX Biosciences, Inc. Common Stock, Common Stock

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana. more

Industry: BiotechnologySector: Health Care

Returns

Time Frame	MBX	Sector	S&P500
1-Week Return	7.5%	-2.12%	-3%
1-Month Return	25.37%	-3.42%	-0.73%
3-Month Return	-9.71%	-11.13%	2.87%
6-Month Return	27.25%	-5.74%	7.17%

Time Frame	MBX	Sector	S&P500
1-Week Return	4,242.37%	-67.28%	-79.57%
1-Month Return	1,465.63%	-34.52%	-8.53%
3-Month Return	-33.92%	-38.03%	12.16%
6-Month Return	63.01%	-11.30%	15.08%

Financials

	Dec '22	Dec '23
Total Revenue	-	-	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue	-	-	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Profit	-	-	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Margin	-	-	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]

Operating Expenses	25.16M	35.31M	[{"date":"2022-12-31","value":71.26,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income	(25.16M)	(35.31M)	[{"date":"2022-12-31","value":-2516100000,"profit":false},{"date":"2023-12-31","value":-3531100000,"profit":false}]
Total Non-Operating Income/Expense	(974.00K)	-	[{"date":"2022-12-31","value":-97400000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Pre-Tax Income	(26.14M)	(32.56M)	[{"date":"2022-12-31","value":-2613500000,"profit":false},{"date":"2023-12-31","value":-3256300000,"profit":false}]
Income Taxes	-	-	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income After Taxes	-	-	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]

Income From Continuous Operations	(26.14M)	(32.56M)	[{"date":"2022-12-31","value":-2613500000,"profit":false},{"date":"2023-12-31","value":-3256300000,"profit":false}]
Income From Discontinued Operations	-	-	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income	(26.14M)	(32.56M)	[{"date":"2022-12-31","value":-2613500000,"profit":false},{"date":"2023-12-31","value":-3256300000,"profit":false}]

EPS (Diluted)	-	-	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]

	Dec '22	Dec '23
Total Revenue	-	-	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue	-	-	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Profit	-	-	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Margin	-	-	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]

Operating Expenses	-	40.34%	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income	-	40.34%	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Total Non-Operating Income/Expense	-	-	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Pre-Tax Income	-	24.60%	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income Taxes	-	-	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income After Taxes	-	-	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]

Income From Continuous Operations	-	24.60%	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income From Discontinued Operations	-	-	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income	-	24.60%	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]

EPS (Diluted)	-	-	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]


Total Revenue	[]
Cost of Revenue	[]
Gross Profit	[]
Gross Margin	[]

Operating Expenses	[]
Operating Income	[]
Total Non-Operating Income/Expense	[]
Pre-Tax Income	[]
Income Taxes	[]
Income After Taxes	[]

Income From Continuous Operations	[]
Income From Discontinued Operations	[]
Net Income	[]

EPS (Diluted)	[]


Total Revenue	[]
Cost of Revenue	[]
Gross Profit	[]
Gross Margin	[]

Operating Expenses	[]
Operating Income	[]
Total Non-Operating Income/Expense	[]
Pre-Tax Income	[]
Income Taxes	[]
Income After Taxes	[]

Income From Continuous Operations	[]
Income From Discontinued Operations	[]
Net Income	[]

EPS (Diluted)	[]

	Dec '22	Dec '23
Total Assets
Current Assets	44.21M	83.47M	[{"date":"2022-12-31","value":52.97,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Non-current Assets	884.00K	715.00K	[{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":80.88,"profit":true}]
Total Assets	45.09M	84.18M	[{"date":"2022-12-31","value":53.57,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]

Total Liabilities
Current Liabilities	3.43M	3.93M	[{"date":"2022-12-31","value":87.39,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Non-current Liabilities	84.27M	152.72M	[{"date":"2022-12-31","value":55.18,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Total Liabilities	87.70M	156.65M	[{"date":"2022-12-31","value":55.99,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]

Total Shareholders' equity
Common Stock	-	-	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Retained Earnings	(43.02M)	(75.58M)	[{"date":"2022-12-31","value":-4302000000,"profit":false},{"date":"2023-12-31","value":-7558300000,"profit":false}]
Other Stockholders' Equity	-	-	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Total Shareholders' equity	(42.60M)	(72.47M)	[{"date":"2022-12-31","value":-4260500000,"profit":false},{"date":"2023-12-31","value":-7246800000,"profit":false}]

Total Liabilities & Shareholders Equity	45.09M	84.18M	[{"date":"2022-12-31","value":53.57,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]

	Dec '22	Dec '23
Total Assets
Current Assets	-	88.79%	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Non-current Assets	-	(19.12%)	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":null,"profit":false}]
Total Assets	-	86.67%	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]

Total Liabilities
Current Liabilities	-	14.43%	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Non-current Liabilities	-	81.23%	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Total Liabilities	-	78.62%	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]

Total Shareholders' equity
Common Stock	-	-	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Retained Earnings	-	75.69%	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Other Stockholders' Equity	-	-	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Total Shareholders' equity	-	70.09%	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]

Total Liabilities & Shareholders Equity	-	86.67%	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]

	Dec '23	Jun '24
Total Assets
Current Assets	83.47M	58.80M	[{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-06-30","value":70.45,"profit":true}]
Non-current Assets	715.00K	4.08M	[{"date":"2023-12-31","value":17.52,"profit":true},{"date":"2024-06-30","value":100,"profit":true}]
Total Assets	84.18M	62.88M	[{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-06-30","value":74.7,"profit":true}]

Total Liabilities
Current Liabilities	3.93M	8.20M	[{"date":"2023-12-31","value":47.89,"profit":true},{"date":"2024-06-30","value":100,"profit":true}]
Non-current Liabilities	152.72M	152.57M	[{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-06-30","value":99.9,"profit":true}]
Total Liabilities	156.65M	160.77M	[{"date":"2023-12-31","value":97.44,"profit":true},{"date":"2024-06-30","value":100,"profit":true}]

Total Shareholders' equity
Common Stock	-	-	[{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}]
Retained Earnings	(75.58M)	(103.78M)	[{"date":"2023-12-31","value":-7558300000,"profit":false},{"date":"2024-06-30","value":-10377700000,"profit":false}]
Other Stockholders' Equity	-	-	[{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}]
Total Shareholders' equity	(72.47M)	(97.89M)	[{"date":"2023-12-31","value":-7246800000,"profit":false},{"date":"2024-06-30","value":-9788500000,"profit":false}]

Total Liabilities & Shareholders Equity	84.18M	62.88M	[{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-06-30","value":74.7,"profit":true}]

	Dec '23	Jun '24
Total Assets
Current Assets	-	(29.55%)	[{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-06-30","value":null,"profit":false}]
Non-current Assets	-	470.77%	[{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-06-30","value":100,"profit":true}]
Total Assets	-	(25.30%)	[{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-06-30","value":null,"profit":false}]

Total Liabilities
Current Liabilities	-	108.81%	[{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-06-30","value":100,"profit":true}]
Non-current Liabilities	-	(0.10%)	[{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-06-30","value":null,"profit":false}]
Total Liabilities	-	2.63%	[{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-06-30","value":100,"profit":true}]

Total Shareholders' equity
Common Stock	-	-	[{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}]
Retained Earnings	-	37.30%	[{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-06-30","value":100,"profit":true}]
Other Stockholders' Equity	-	-	[{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}]
Total Shareholders' equity	-	35.07%	[{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-06-30","value":100,"profit":true}]

Total Liabilities & Shareholders Equity	-	(25.30%)	[{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-06-30","value":null,"profit":false}]

	Dec '22	Dec '23
Operating Activities
Net Operating Cash Flow	(23.12M)	(31.98M)	[{"date":"2022-12-31","value":-2312200000,"profit":false},{"date":"2023-12-31","value":-3197800000,"profit":false}]

Investing Activities
Net Investing Cash Flow	-	-	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]

Financing Activities
Net Financing Cash Flow	46.06M	69.22M	[{"date":"2022-12-31","value":66.55,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]

Net Change in Cash	11.53M	6.31M	[{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":54.75,"profit":true}]

Free Cash Flow
Free Cash Flow	(23.56M)	(32.11M)	[{"date":"2022-12-31","value":-2356300000,"profit":false},{"date":"2023-12-31","value":-3210700000,"profit":false}]

	Dec '22	Dec '23
Operating Activities
Net Operating Cash Flow	-	38.30%	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]

Investing Activities
Net Investing Cash Flow	-	-	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]

Financing Activities
Net Financing Cash Flow	-	50.27%	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]

Net Change in Cash	-	(45.25%)	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":null,"profit":false}]

Free Cash Flow
Free Cash Flow	-	36.26%	[{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

	MBX
Current Ratio	7.17

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

	MBX
ROA (LTM)	0.00%
ROE (LTM)	0.00%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

	MBX
Debt Ratio Lower is generally better. Negative is bad.	2.56
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier.	-1.56

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

	MBX
Trailing PE	NM
Forward PE	NM
P/S (TTM)	0.00
P/B	0.00
EV/R	0.00
EV/Ebitda	NM

Discover more

Tesla, Inc.

Apple, Inc.

Alphabet Inc. - Class A Shares

Meta Platforms Inc

Amazon.com Inc.

Microsoft Corporation

NVIDIA Corporation

Berkshire Hathaway Inc. Hld B

Eli Lilly and Company

FAQs

What is MBX Biosciences, Inc. Common Stock share price today?

MBX Biosciences, Inc. Common Stock (MBX) share price today is $20.36

Can Indians buy MBX Biosciences, Inc. Common Stock shares?

Yes, Indians can buy shares of MBX Biosciences, Inc. Common Stock (MBX) on Vested. To buy MBX Biosciences, Inc. Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MBX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of MBX Biosciences, Inc. Common Stock be purchased?

Yes, you can purchase fractional shares of MBX Biosciences, Inc. Common Stock (MBX) via the Vested app. You can start investing in MBX Biosciences, Inc. Common Stock (MBX) with a minimum investment of $1.

How to invest in MBX Biosciences, Inc. Common Stock shares from India?

You can invest in shares of MBX Biosciences, Inc. Common Stock (MBX) via Vested in three simple steps:

Click on Sign Up or Invest in MBX stock at the top of this page
Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
Transfer USD funds to your US Brokerage account and start investing in MBX Biosciences, Inc. Common Stock shares

What is MBX Biosciences, Inc. Common Stock 52-week high and low stock price?

The 52-week high price of MBX Biosciences, Inc. Common Stock (MBX) is $27.5. The 52-week low price of MBX Biosciences, Inc. Common Stock (MBX) is $15.31.

What is MBX Biosciences, Inc. Common Stock price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of MBX Biosciences, Inc. Common Stock (MBX) is

What is MBX Biosciences, Inc. Common Stock price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of MBX Biosciences, Inc. Common Stock (MBX) is 0.00

What is MBX Biosciences, Inc. Common Stock dividend yield?

The dividend yield of MBX Biosciences, Inc. Common Stock (MBX) is 0.00%

What is the Market Cap of MBX Biosciences, Inc. Common Stock?

The market capitalization of MBX Biosciences, Inc. Common Stock (MBX) is $676.25M

What is MBX Biosciences, Inc. Common Stock’s stock symbol?

The stock symbol (or ticker) of MBX Biosciences, Inc. Common Stock is MBX